Tamburini
Andrea Tamburini, San Donato Milanese (mi) IT
Patent application number | Description | Published |
---|---|---|
20130093610 | APPARATUS FOR MEASURING THE EARTH SURFACE MOVEMENT BY MEANS OF SAR IMAGES WITH AT LEAST ONE ELECTROMAGNETIC WAVE REFLECTOR - An apparatus is described for measuring the earth surface movement by means of SAR images; the apparatus comprises at least one SAR radar ( | 04-18-2013 |
Beth Tamburini, Lakewood, CO US
Patent application number | Description | Published |
---|---|---|
20150196626 | MODULATION OF YEAST-BASED IMMUNOTHERAPY PRODUCTS AND RESPONSES - Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions. | 07-16-2015 |
Beth Tamburini, Denver, CO US
Patent application number | Description | Published |
---|---|---|
20120321664 | MODULATION OF YEAST-BASED IMMUNOTHERAPY PRODUCTS AND RESPONSES - Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions. | 12-20-2012 |
Christophe Tamburini, Saint Laurent De Mure FR
Patent application number | Description | Published |
---|---|---|
20150142115 | VERTEBRAL IMPLANT PROVIDED WITH A SELF-LOCKING AND UNLOCKING MEANS - The invention relates to a vertebral implant ( | 05-21-2015 |
Cinzia Tamburini, Rimini IT
Patent application number | Description | Published |
---|---|---|
20110018264 | ENERGY CONVERSION AND ACCUMULATION DEVICE AND RELATIVE METHOD - An energy conversion and accumulation device, for the conversion of environmental energy into electric energy, includes a transducer, able to convert external environmental stress into an electric quantity, a storage element to accumulate and/or transfer the electric quantity to an electric device, a first switch element, activated in order to transfer electric energy from the transducer directly to a temporary storage element, and a second switch element activated in order to transfer electric energy stored by the temporary storage element directly to the storage element. The device further includes a sensor element, associated with the transducer, temporary storage element, and storage element. The sensor element detects predetermined energy conditions favorable for the selective and/or mutually alternate activation of the switch elements for a corresponding alternate electric energy transfer respectively from the transducer to the temporary storage element and from the temporary storage element to the storage element. | 01-27-2011 |
Fabrizio Tamburini, Venezia IT
Patent application number | Description | Published |
---|---|---|
20150191372 | METHOD AND PLANT FOR THE REDUCTION OF THE CONCENTRATION OF POLLUTANTS AND/OR VALUABLE ELEMENTS IN THE WATER - The present invention concerns a method for reducing the amount of polluting and/or valuable elements through application of electrolysis, in particular of the electrocapturing phenomenon. The electrolysis according to the present invention is applied permanently over time in a polluted water body. The predetermined action area ( | 07-09-2015 |
Paul Tamburini, Kensington, CT US
Patent application number | Description | Published |
---|---|---|
20100129315 | Anti-MN Antibodies and Methods of Using Same - The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods for using such antibodies in treating and diagnosing an MN-related disorder. | 05-27-2010 |
20120301468 | ANTI-MN ANTIBODIES AND METHODS OF USING SAME - The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods of using such antibodies in treating and diagnosing an MN-related disorder. | 11-29-2012 |
Paul P. Tamburini, Kensington, CT US
Patent application number | Description | Published |
---|---|---|
20110002931 | BISPECIFIC ANTIBODIES THAT BIND TO COMPLEMENT PROTEINS - The present disclosure relates to bispecific antibodies that can bind to two or more different epitopes. For example, the bispecific antibodies described herein can bind to two or more different proteins, wherein at least two of the proteins are selected from C5a, C5b, a cellular receptor for C5a (e.g., C5aR1 or C5L2), the C5b-9 complex, and a component or intermediate of terminal complement such as C5b-6, C5b-7, or C5b-8. The bispecific antibodies described herein are useful for, e.g., inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 complex) and/or C5a anaphylatoxin-mediated inflammation (e.g., C5a-mediated chemotaxis of inflammatory immune cells). Accordingly, the bispecific antibodies can be used in methods for treating a variety of complement pathway-associated disorders. | 01-06-2011 |
20130224187 | ANTI-C5a ANTIBODIES AND METHODS FOR USING THE ANTIBODIES - The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease. | 08-29-2013 |
20140206849 | ANTIBODIES HAVING REDUCED IMMUNOGENICITY IN A HUMAN - The disclosure relates to engineered antibodies that when administered to a human, exhibit a low level of immunogenicity in the human. The disclosure also relates to methods for generating the antibodies. The engineered antibodies can be derived from, e.g., on-human (e.g., murine) donor antibodies or from chimeric or humanized antibodies that, when chronically administered to a human, are known to, are predicted to, or are expected to, elicit a neutralizing anti-antibody response in the human. | 07-24-2014 |
20150183859 | ANTI-C5A ANTIBODIES AND METHODS FOR USING THE ANTIBODIES - The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease. | 07-02-2015 |
20150247849 | SCREENING ASSAYS FOR COMPLEMENT COMPONENT C5 ANTAGONISTS - Disclosed herein are compositions and methods for screening for novel compounds that bind to polypeptides of therapeutic interest (e.g., polypeptides implicated in, or known to contribute to, the pathogenesis of human disease). In some embodiments, the compounds bind to a component of the human complement cascade such as human complement component C5. In some embodiments, the compounds so identified inhibit complement-mediated activity and are potential drug candidates for treating complement-associated disorders. This disclosure also provides compositions and methods for screening for novel compounds that inhibit complement-mediated activity and may be useful for identifying potential drug candidates for treating patients showing little or no response to the existing therapies for treating complement associated disorders. | 09-03-2015 |
Paul P. Tamburini US
Patent application number | Description | Published |
---|---|---|
20150247849 | SCREENING ASSAYS FOR COMPLEMENT COMPONENT C5 ANTAGONISTS - Disclosed herein are compositions and methods for screening for novel compounds that bind to polypeptides of therapeutic interest (e.g., polypeptides implicated in, or known to contribute to, the pathogenesis of human disease). In some embodiments, the compounds bind to a component of the human complement cascade such as human complement component C5. In some embodiments, the compounds so identified inhibit complement-mediated activity and are potential drug candidates for treating complement-associated disorders. This disclosure also provides compositions and methods for screening for novel compounds that inhibit complement-mediated activity and may be useful for identifying potential drug candidates for treating patients showing little or no response to the existing therapies for treating complement associated disorders. | 09-03-2015 |